journal article·2022-08Open access

Harnessing chitosan and poly-(γ-glutamic acid)-based biomaterials towards cancer immunotherapy

Beatriz V. Lima, Maria J. Oliveira, Mário A. Barbosa, Raquel M. Gonçalves, Flávia Castro

Abstract

Cancer-related immunosuppression is one of the most challenging aspects of cancer therapy, being one of the principal causes of disease relapse. Most recent immunotherapeutic strategies have been at the forefront of therapies to overcome this problem through targeting T cell-related pathways. Notwithstanding their remarkable clinical success, current immunotherapies have still benefited a small percentage of patients. As such, considering solid tumors are virtually infiltrated by a high proportion of innate immune cells, frequently mentioned as masters of immunosuppression, targeting these cells may offer a durable immune response. Thus, finding new strategies to reprogram the function of innate immune system in the tumor microenvironment is still an unmet clinical need. Biomaterials-based immunomodulatory therapies have been increasingly explored to achieve better cancer treatments. In particular, chitosan (Ch), a polysaccharide derived from the deacetylation of chitin, as well as poly-γ-glutamic acid (γ-PGA), a polymer bacterially synthetized, that can spontaneously self-assemble by electrostatic interactions in different structures, have been preclinically explored for their immunomodulatory properties. Ch and γ-PGA have been found to activate Toll-like receptors, and trigger common pro-inflammatory immune pathways, such as Nuclear factor kappa B (NF-кB) and Mitogen-activated protein kinase (MAPK). Other pathways and receptors, such as the Retinoic Acid Orphan Receptor γt (RORγt), phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT), or the inflammasome have also been shown to be differentially activated by either polymer. Hence the prospective application of Ch/γ-PGA formulations in cancer therapy, in an effort to synergize their effects to heighten the therapeutic response via innate immunity, could constitute a novel immunotherapeutic strategy. This review highlights how Ch and γ-PGA can efficiently reprogram innate immune cells in tumors, and ultimately initiate activation of T cell immunity against advanced cancers. Moreover, the therapeutic potential of Ch/γ-PGA-based biomaterials as adjuvants of conventional cancer therapies and as diagnostic tools is discussed.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Biopolymer Synthesis and Applications · RNA Interference and Gene Delivery · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Turning cold into hot: firing up the tumor microenvironment10.1016/j.trecan.2020.02.022 ↗
2. Integrating the tumor microenvironment into cancer therapy10.3390/cancers12061677 ↗
3. The tumor microenvironment at a glance10.1242/jcs.116392 ↗
4. Cancer and the immune system: the history and background of immunotherapy10.1016/j.soncn.2019.08.002 ↗
5. The immune system and cancer evasion strategies: therapeutic concepts10.1111/joim.12470 ↗
6. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion10.1126/science.1203486 ↗
7. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy10.1093/annonc/mdw168 ↗
8. The fight against cancer: is harnessing the immune system the ultimate strategy?10.12968/hmed.2019.80.10.568 ↗
9. The History and Advances in Cancer Immunotherapy: Understanding the Characteristics of Tumor-Infiltrating Immune Cells and Their Therapeutic Implications10.1038/s41423-020-0488-6 ↗
10. Molecules in cancer immunotherapy: benefits and side effects10.1136/jclinpath-2018-205370 ↗
11. Safety and tolerability of adoptive cell therapy in cancer10.1007/s40264-018-0779-3 ↗
12. Adverse events in cancer immunotherapy10.1007/978-3-319-53156-4_8 ↗
13. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations10.3389/fonc.2018.00086 ↗
14. Mutational landscape and sensitivity to immune checkpoint blockers10.1158/1078-0432.CCR-16-0903 ↗
15. Improving vaccine and immunotherapy design using biomaterials10.1016/j.it.2017.10.002 ↗
16. Chitin, Chitosan, and Glycated Chitosan Regulate Immune Responses: the Novel Adjuvants for Cancer Vaccine
17. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination10.1016/j.vaccine.2006.11.034 ↗
18. The natural product chitosan enhances the anti-tumor activity of natural killer cells by activating dendritic cells10.1080/2162402X.2018.1431085 ↗
19. Polysaccharides as vaccine adjuvants10.1016/j.vaccine.2018.07.040 ↗
20. Immunomodulatory potential of chitosan-based materials for cancer therapy: a systematic review of in vitro, in vivo and clinical studies10.1039/D0BM01984D ↗
21. Bacterial-derived polymer poly-y-glutamic acid (y-PGA)-Based micro/nanoparticles as a delivery system for antimicrobials and other biomedical applications10.3390/ijms18020313 ↗
22. Intranasal administration of poly-gamma glutamate induced antiviral activity and protective immune responses against H1N1 influenza A virus infection10.1186/s12985-015-0387-0 ↗
23. Immunomodulatory effect of poly-gamma-glutamic acid derived from Bacillus subtilis on natural killer dendritic cells10.1016/j.bbrc.2013.11.097 ↗
24. An interferon-gamma-delivery system based on chitosan/poly(gamma-glutamic acid) polyelectrolyte complexes modulates macrophage-derived stimulation of cancer cell invasion in vitro10.1016/j.actbio.2015.05.022 ↗
25. Pro-inflammatory chitosan/poly(gamma-glutamic acid) nanoparticles modulate human antigen-presenting cells phenotype and revert their pro-invasive capacity10.1016/j.actbio.2017.09.016 ↗
26. Chitosan/poly(gamma-glutamic acid) nanoparticles incorporating IFN-gamma for immune response modulation in the context of colorectal cancer10.1039/C9BM00393B ↗
27. Chitosan/γ-PGA nanoparticles-based immunotherapy as adjuvant to radiotherapy in breast cancer10.1016/j.biomaterials.2020.120218 ↗
28. MHC class II antigen presentation by dendritic cells regulated through endosomal sorting10.1101/cshperspect.a016873 ↗
29. Toll-like receptors10.1016/j.cub.2011.05.039 ↗
30. Inflammasome activation and assembly at a glance10.1242/jcs.207365 ↗
31. C-type lectin receptor: old friend and new player10.2174/1573406413666170510103030 ↗
32. Conjugation of chitosan oligosaccharides enhances immune response to porcine circovirus vaccine by activating macrophages10.1016/j.imbio.2018.07.012 ↗
33. Toll like receptor 4 (TLR4) mediates the stimulating activities of chitosan oligosaccharide on macrophages10.1016/j.intimp.2014.09.007 ↗
34. Effect of chitosan molecular weight on anti-inflammatory activity in the RAW 264.7 macrophage model10.1016/j.ijbiomac.2019.02.066 ↗
35. Chitosan oligosaccharides suppressant LPS binding to TLR4/MD-2 receptor complex10.1016/j.carbpol.2010.04.079 ↗
36. Lysosomal rupture induced by structurally distinct chitosans either promotes a type 1 IFN response or activates the inflammasome in macrophages10.1016/j.biomaterials.2017.03.022 ↗
37. Spectrum and mechanisms of inflammasome activation by chitosan10.4049/jimmunol.1301695 ↗
38. Chitosan but not chitin activates the inflammasome by a mechanism dependent upon phagocytosis10.1074/jbc.M111.274936 ↗
39. 3D chitosan scaffolds impair NLRP3 inflammasome response in macrophages10.1016/j.actbio.2019.04.035 ↗
40. Potential role of nuclear factor-kappaB in the induction of nitric oxide nd tumor necrosis factor-alpha by oligochitosan in macrophages10.1016/j.intimp.2003.12.001 ↗
41. Molecular weight-dependent immunostimulative activity of low molecular weight chitosan via regulating NF-kappaB and AP-1 signaling pathways in RAW264.7 macrophages10.3390/md14090169 ↗
42. Nitric oxide production by high molecular weight water-soluble chitosan via nuclear factor-κB activation10.1016/S0192-0561(00)00055-2 ↗
43. Immunostimulatory effects of chitooligosaccharides on RAW 264.7 mouse macrophages via regulation of the MAPK and PI3K/akt signaling pathways10.3390/md17010036 ↗
44. Immunostimulatory effects of sulfated chitosans on RAW 264.7 mouse macrophages via the activation of PI3K/Akt signaling pathway10.1016/j.ijbiomac.2017.11.042 ↗
45. Chitosan oligosaccharides inhibit LPS-induced over-expression of IL-6 and TNF-α in RAW264.7 macrophage cells through blockade of mitogen-activated protein kinase (MAPK) and PI3K/Akt signaling pathways10.1016/j.carbpol.2011.01.045 ↗
46. Involvement of Nrf2-mediated heme oxygenase-1 expression in anti-inflammatory action of chitosan oligosaccharides through MAPK activation in murine macrophages10.1016/j.ejphar.2016.11.002 ↗
47. The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons10.1016/j.immuni.2016.02.004 ↗
48. Chitosan induces different l-arginine metabolic pathways in resting and inflammatory macrophages10.1016/S0006-291X(03)00579-5 ↗
49. Biodegradable chitosan microparticles induce delayed STAT-1 activation and lead to distinct cytokine responses in differentially polarized human macrophages in vitro10.1016/j.actbio.2014.10.026 ↗
50. Fungal cell wall agents suppress the innate inflammatory cytokine responses of human peripheral blood mononuclear cells challenged with lipopolysaccharide in vitro10.1016/j.intimp.2011.02.006 ↗
51. Potential therapeutic targets for inflammation in toll-like receptor 4 (TLR4)-mediated signaling pathways10.1016/j.intimp.2016.08.026 ↗
52. LPS/TLR4 signal transduction pathway10.1016/j.cyto.2008.01.006 ↗
53. Role of nitric oxide produced by iNOS through NF-kappaB pathway in migration of cerebellar granule neurons induced by Lipopolysaccharide10.1016/j.cellsig.2010.10.017 ↗
54. Biological effects and applications of chitosan and chito-oligosaccharides10.3389/fphys.2019.00516 ↗
55. The role of Toll-like receptor 2 in microbial disease and immunity10.1016/S0264-410X(03)00201-9 ↗
56. Mechanism and regulation of NLRP3 inflammasome activation10.1016/j.tibs.2016.09.002 ↗
57. NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms10.1016/j.blre.2016.10.001 ↗
58. Control of macrophage metabolism and activation by mTOR and Akt signaling10.1016/j.smim.2015.08.001 ↗
59. Regulation of JNK and p38 MAPK in the immune system: signal integration, propagation and termination10.1016/j.cyto.2009.08.002 ↗
60. ERK/MAPK signalling pathway and tumorigenesis
61. Mitogen-activated protein kinases in innate immunity10.1038/nri3495 ↗
62. JNK signaling: regulation and functions based on complex protein-protein partnerships10.1128/MMBR.00043-14 ↗
63. p38 MAPK signalling cascades in inflammatory disease10.1016/S1357-4310(99)01544-0 ↗
64. AP-1 expression and its clinical relevance in immune disorders and cancer10.1016/j.amjms.2017.01.019 ↗
65. Arginine metabolism in myeloid cells shapes innate and adaptive immunity10.3389/fimmu.2017.00093 ↗
66. The induction of innate and adaptive immunity by biodegradable poly(gamma-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway10.1016/j.biomaterials.2011.03.052 ↗
67. Bacillus subtilis-specific poly-gamma-glutamic acid regulates development pathways of naive CD4(+) T cells through antigen-presenting cell-dependent and -independent mechanisms10.1093/intimm/dxp065 ↗
68. Bacillus-derived poly-gamma-glutamic acid attenuates allergic airway inflammation through a Toll-like receptor-4-dependent pathway in a murine model of asthma10.1111/j.1365-2222.2011.03792.x ↗
69. Bacillus-derived poly-gamma-glutamic acid reciprocally regulates the differentiation of T helper 17 and regulatory T cells and attenuates experimental autoimmune encephalomyelitis10.1111/j.1365-2249.2012.04637.x ↗
70. The antiviral activity of poly-gamma-glutamic acid, a polypeptide secreted by Bacillus sp., through induction of CD14-dependent type I interferon responses10.1016/j.biomaterials.2013.08.067 ↗
71. Prophylactic efficacy of orally administered Bacillus poly-gamma-glutamic acid, a non-LPS TLR4 ligand, against norovirus infection in mice10.1038/s41598-018-26935-y ↗
72. Infection-mimicking poly(gamma-glutamic acid) as adjuvant material for effective anti-tumor immune response10.1016/j.ijbiomac.2015.02.013 ↗
73. Poly-gamma-glutamic acid from Bacillus subtilis upregulates pro-inflammatory cytokines while inhibiting NLRP3, NLRC4 and AIM2 inflammasome activation10.1038/cmi.2016.13 ↗
74. Human innate immune cells respond differentially to poly-gamma-glutamic acid polymers from Bacillus anthracis and nonpathogenic Bacillus species10.4049/jimmunol.1901066 ↗
75. Aminated nanomicelles as a designer vaccine adjuvant to trigger inflammasomes and multiple arms of the innate immune response in lymph nodes10.2147/IJN.S144623 ↗
76. Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity10.4049/jimmunol.178.5.2979 ↗
77. Poly-gamma-glutamic acid attenuates angiogenesis and inflammation in experimental colitis10.1155/2013/982383 ↗
78. Type I interferons in host defence and inflammatory diseases10.1136/lupus-2019-000336 ↗
79. Molecular size hyaluronan differently modulates toll-like receptor-4 in LPS-induced inflammation in mouse chondrocytes10.1016/j.biochi.2009.10.006 ↗
80. FOXP3 and RORγt: transcriptional regulation of Treg and Th1710.1016/j.intimp.2010.11.008 ↗
81. Regulation of RORgammat in inflammatory lymphoid cell differentiation10.1101/sqb.2015.80.027615 ↗
82. The good, the bad and the ugly" of chitosans10.3390/md14050099 ↗
83. Natural and edible biopolymer poly-gamma-glutamic acid: synthesis, production, and applications10.1002/tcr.20061 ↗
84. Layer-by-layer self-assembly of chitosan and poly(gamma-glutamic acid) into polyelectrolyte complexes10.1021/bm2008235 ↗
85. Biopolymer based nanosystem for doxorubicin targeted delivery
86. Fabrication and release behavior of a novel freeze-gelled chitosan/gamma-PGA scaffold as a carrier for rhBMP-210.1016/j.dental.2005.05.012 ↗
87. Improving solubility, stability, and cellular uptake of resveratrol by nanoencapsulation with chitosan and gamma-poly (glutamic acid)10.1016/j.colsurfb.2016.07.062 ↗
88. Chitosan/gamma-poly(glutamic acid) scaffolds with surface-modified albumin, elastin and poly-l-lysine for cartilage tissue engineering, Materials science & engineering
89. Enhanced stability of oral insulin in targeted peptide ligand trimethyl chitosan nanoparticles against trypsin10.3109/02652048.2015.1065920 ↗
90. Polyelectrolyte complex nanofibers from poly(gamma-glutamic acid) and fluorescent chitosan oligomer10.1016/j.ijbiomac.2018.06.035 ↗
91. Layered hydrogel of poly(gamma-glutamic acid), sodium alginate, and chitosan: fluorescence observation of structure and cytocompatibility10.1016/j.colsurfb.2011.04.002 ↗
92. Preliminary investigation on a new natural based poly(gamma-glutamic acid)/Chitosan bioink10.1002/jbm.b.34602 ↗
93. Poly-gamma-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine10.1038/srep44839 ↗
94. Nanoparticles incorporated in pH-sensitive hydrogels as amoxicillin delivery for eradication of Helicobacter pylori10.1021/bm900985h ↗
95. Dual-layered nanogel-coated hollow lipid/polypeptide conjugate assemblies for potential pH-triggered intracellular drug release10.1371/journal.pone.0092268 ↗
96. Single dose HBsAg CS-gamma-PGA nanogels induce potent protective immune responses against HBV infection10.1016/j.ejpb.2017.12.003 ↗
97. Preparation of gamma-PGA/chitosan composite tissue engineering matrices10.1016/j.biomaterials.2005.02.012 ↗
98. Poly(gamma-Glutamic acid)/chitosan hydrogel nanoparticles for effective preservation and delivery of fermented herbal extract for enlarging hair bulb and enhancing hair growth10.2147/IJN.S227514 ↗
99. Injectable system and its potential application for the delivery of biomolecules by using thermosensitive poly(gamma-glutamic acid)-based physical hydrogel10.1016/j.ijbiomac.2017.09.108 ↗
100. Bioresponsive materials for drug delivery based on carboxymethyl chitosan/poly(gamma-glutamic acid) composite microparticles10.3390/md15050127 ↗